Story perspectives

Research Links Microbiome to CAR T-Cell Therapy Success

2/23/2025

42 9

Summary

Dr. Smith's Research

Dr. Melody Smith's groundbreaking research at the American Association for Cancer Research Immunotherapy Conference reveals a crucial link between the intestinal microbiome and the effectiveness of CAR T-cell therapy. Alarmingly, antibiotic use, especially against obligate anaerobes, worsens survival rates and heightens neurotoxicity. Future investigations may focus on dietary changes and microbiome profiling to boost treatment success and minimize side effects.

Summary

CAR-T Patients' COVID Risks

During the Omicron wave, a study revealed that 65.3% of BCMA-targeted CAR-T cell recipients contracted COVID-19, with 18.8% facing severe illness. Older age heightened the risk of severity, yet those who achieved a complete response from therapy showed better protection. The findings underscore the urgent need for preventive measures for vulnerable patients.

1 of 2

Dr. Smith's Research

Dr. Melody Smith's groundbreaking research at the American Association for Cancer Research Immunotherapy Conference reveals a crucial link between the intestinal microbiome and the effectiveness of CAR T-cell therapy. Alarmingly, antibiotic use, especially against obligate anaerobes, worsens survival rates and heightens neurotoxicity. Future investigations may focus on dietary changes and microbiome profiling to boost treatment success and minimize side effects.

1 / 2